(S039) High-Resolution 4D Ventilation and Perfusion PET/CT Facilitates Functionally Adapted Intensity-Modulated Radiation Therapy (IMRT) in Lung Cancer

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

IMRT plans that were adapted to perfused but not ventilated lung on 4D-V/Q PET/CT allowed for reduced dose to the functional lung while maintaining consistent plan quality.

David Ball, MD; Peter MacCallum Cancer Centre

PURPOSE: To assess the utility of functional lung avoidance using intensity-modulated radiation therapy (IMRT) informed by four-dimensional ventilation/perfusion positron emission tomography/computed tompgraphy (4D-V/Q PET/CT) in patients with non–small-cell lung cancer (NSCLC).

MATERIALS AND METHODS: In a prospective clinical trial, patients underwent 4D-V/Q PET/CT scanning before 60 Gy of definitive chemoradiation. Both “highly perfused” (HPLung) and “highly ventilated” (HVLung) lung volumes were delineated using a visually adapted 70th percentile standardized uptake value (SUV) threshold method. The HVLung was universally smaller than HPLung; so, a “ventilated lung volume” (VLung) was created to approximate the HPLung using a 50th percentile SUV threshold. For each patient, four IMRT plans were created, optimized to the anatomical lung, HPLung, VLung, and HPLung volumes. IMRT that was optimized to the anatomical lung was compared with functionally adapted IMRT using functional lung volumetrics, including mean lung dose (MLD), V5, V10, V20, V30, V40, V50, and V60 parameters. Plan quality was assessed by dose to 95% and 5% of planning target volume (PTV) (D95 and D5), conformity index (CI), and heterogeneity index (HI).

RESULTS: The study cohort consisted of 20 patients with 80 IMRT plans. The mean (+/– SD) lung volume for the HPLung and VLung was similar at 1,876 cc (+/– 677 cc) and 1,904 cc (+/– 505 cc), respectively, while HVLung was smaller at 932 cc (+/– 258 cc). Plans that were optimized to HPLung resulted in a significant reduction of functional MLD by a mean of 13.0% (1.7 Gy; P = .02). Functional V5, V10, and V20 were improved by 13.2%, 7.3%, and 3.8%, respectively (P < .04). There was no sparing of dose to functional lung when adapting to VLung or HVLung. Plan quality was highly consistent with a mean PTV D95 and D5, ranging from 60.8–61.0 Gy and 63.4–64.5 Gy, respectively, and with mean CI and HI ranging from 1.11–1.17 and 0.94–0.95, respectively.

CONCLUSIONS: IMRT plans that were adapted to perfused but not ventilated lung on 4D-V/Q PET/CT allowed for reduced dose to the functional lung while maintaining consistent plan quality.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Related Content